GlassScriptPhysician profile
Steven Zygmont
NPI 1114965860
$167,167.86
in general payments reported to CMS, 2019-2025
40 companies · $3,090 in 2025
The $3,090 reported for 2025 was more than what 83% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67K · 2020: $21K · 2021: $38K · 2022: $7,595 · 2023: $16K · 2024: $15K · 2025: $3,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $4,103 · Travel and Lodging: $1,707 · Education: $24.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,512.50 |
| Food and Beverage | $4,102.51 |
| Travel and Lodging | $1,707.05 |
| Education | $24.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $65,464.21 | 2019-2024 | Farxiga, Airsupra |
| Novo Nordisk INC | $43,162.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30,928.69 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $19,945.01 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $2,476.08 | 2019-2025 | Gardasil 9, Capvaxive |
| Medtronic, INC. | $1,687.02 | 2024-2025 | Minimed 780g |
| Abbott Laboratories | $413.48 | 2019-2025 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $327.57 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $303.97 | 2019-2025 | Omnipod |
| Amgen INC. | $297.38 | 2019-2025 | Evenity, Tepezza, Repatha |
| Dexcom, INC. | $277.28 | 2021-2024 | Dexcom G6 Transmitter |
| Mannkind Corporation | $196.61 | 2021-2025 | |
| Medtronic Minimed, INC. | $176.11 | 2019-2020 | |
| Beta Bionics, INC. | $142.65 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Corcept Therapeutics | $124.90 | 2023-2025 | Korlym |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $116.08 | 2025 | Strensiq |
| Horizon Therapeutics Plc | $114.25 | 2023 | Tepezza |
| Sanofi-Aventis U.S. LLC | $111.89 | 2019-2025 | |
| Pfizer INC. | $105.73 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $73.50 | 2025 | Recorlev |
| Amneal Pharmaceuticals LLC | $71.82 | 2023-2025 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $60.82 | 2024-2025 | |
| Sequel Med Tech, LLC | $60.25 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $57.25 | 2025 | Yorvipath |
| Kyowa Kirin, INC. | $55.71 | 2025 | |
| Radius Health, INC. | $49.82 | 2019-2025 | |
| Amphastar Pharmaceuticals, INC. | $44.29 | 2025 | |
| Cequr Corporation | $41.52 | 2024-2025 | Cequr Simplicity |
| Chiesi USA, INC. | $40.01 | 2025 | Mycapssa |
| Ibsa Pharma INC. | $36.96 | 2025 | Tirosint, Licart, Flector |
| Tolmar, INC. | $32.41 | 2024 | |
| Almatica Pharma LLC | $25.32 | 2025 | Teriparatide |
| Sandoz INC. | $24.32 | 2025 | |
| Amarin Pharma, INC. | $22.37 | 2019 | |
| Inspire Medical Systems, INC. | $20.73 | 2024 | Inspire |
| Recordati_rare_diseases_inc. | $20.08 | 2025 | Isturisa |
| Abbvie INC. | $17.24 | 2024 | |
| Glaxosmithkline, LLC. | $15.69 | 2025 | Shingrix, Arexvy |
| Antares Pharma, INC. | $13.55 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Zygmont listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.